2023
Sex and age differences in sST2 in cardiovascular disease
BEETLER, Danielle J, Katelyn A BRUNO, Damian N DI FLORIO, Erika J DOUGLASS, Swikriti SHRESTHA et. al.Základní údaje
Originální název
Sex and age differences in sST2 in cardiovascular disease
Autoři
BEETLER, Danielle J, Katelyn A BRUNO, Damian N DI FLORIO, Erika J DOUGLASS, Swikriti SHRESTHA, Carsten TSCHOEPE, Madeleine W CUNNINGHAM, Jan KREJČÍ (203 Česká republika, domácí), Julie DOBROVOLNÁ (203 Česká republika, domácí), Sabine PANKUWEIT, Dennis M MCNAMARA, Eun-Seok JEON, van Linthout SOPHIE, Lori A BLAUWET, Leslie T Jr COOPER a DeLisa FAIRWEATHER
Vydání
Frontiers in Cardiovascular Medicine, Lausanne, Frontiers Media SA, 2023, 2297-055X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.600 v roce 2022
Kód RIV
RIV/00216224:14110/23:00134703
Organizační jednotka
Lékařská fakulta
UT WoS
000923390600001
Klíčová slova anglicky
biomarkers; heart failure; myocardial infarct; coronary artery disease; cardiomyopathy; congestive heart failure
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 2. 2. 2024 08:48, Mgr. Tereza Miškechová
Anotace
V originále
AimsThe goal of this study was to determine whether sex and age differences exist for soluble ST2 (sST2) for several cardiovascular diseases (CVDs). MethodsWe examined sST2 levels using an ELISA kit for myocarditis (n = 303), cardiomyopathy (n = 293), coronary artery disease (CAD) (n = 239), myocardial infarct (MI) (n = 159), and congestive heart failure (CHF) (n = 286) and compared them to controls that did not have CVDs (n = 234). ResultsMyocarditis occurred in this study in relatively young patients around age 40 while the other CVDs occurred more often in older individuals around age 60. We observed a sex difference in sST2 by age only in myocarditis patients (men aged 38, women 46, p = 0.0002), but not for other CVDs. Sera sST2 levels were significantly elevated compared to age-matched controls for all CVDs: myocarditis (p <= 0.0001), cardiomyopathy (p = 0.0009), CAD (p = 0.03), MI (p = 0.034), and CHF (p < 0.0001) driven by elevated sST2 levels in females for all CVDs except myocarditis, which was elevated in both females (p = 0.002) and males (p <= 0.0001). Sex differences in sST2 levels were found for myocarditis and cardiomyopathy but no other CVDs and were higher in males (myocarditis p = 0.0035; cardiomyopathy p = 0.0047). sST2 levels were higher in women with myocarditis over 50 years of age compared to men (p = 0.0004) or women under 50 years of age (p = 0.015). In cardiomyopathy and MI patients, men over 50 had significantly higher levels of sST2 than women (p = 0.012 and p = 0.043, respectively) but sex and age differences were not detected in other CVDs. However, women with cardiomyopathy that experienced early menopause had higher sST2 levels than those who underwent menopause at a natural age range (p = 0.02). ConclusionWe found that sex and age differences in sera sST2 exist for myocarditis, cardiomyopathy, and MI, but were not observed in other CVDs including CAD and CHF. These initial findings in patients with self-reported CVDs indicate that more research is needed into sex and age differences in sST2 levels in individual CVDs.
Návaznosti
NU22-02-00418, projekt VaV |
|